Clinical Trial: Lifemel Honey to Reduce Leucopenia During Chemotherapy

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

Brief Summary: This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Detailed Summary:
Sponsor: Rambam Health Care Campus

Current Primary Outcome: Prevention of myelotoxicity-every week during chemotherapy.

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Rambam Health Care Campus

Dates:
Date Received: October 20, 2005
Date Started: November 2005
Date Completion:
Last Updated: December 4, 2009
Last Verified: October 2005